PBL continues to supply Erwinase® finished product batches on time.
PBL has made significant investment in resources and devoted effort into ensuring that it manufactures and delivers its life-saving product Erwinase® on schedule.
Table of finished product batches
|DP Batch number||Batch Manufactured||Batch available for collection|
|191||Thursday 29th November 2018|
|192||Friday 25th January 2019|
|193||Tuesday 9th April 2019|
|194||Wednesday 12th June 2019|
|195||Friday 9th August 2019|
|196||Tuesday 12th November 2019|
|197||Friday 27th September 2019|
|198||Friday 15th November|
|199||Monday 9th December|
|200||Product filled QC testing ongoing||–|
* planned within the current financial year
PBL staff across the whole company are committed to the importance of making batches available on time for release to our current sales and distribution partner Jazz Pharmaceuticals. Erwinase® is a critical healthcare product essential to children fighting acute lymphoblastic leukaemia which is the commonest form of childhood cancer.
As part of our commitment, PBL has, during the last year introduced new product components including bromo-butyl stoppers and 3ml type 1 borosilicate clear-glass vials to improve compliance, ensure our product conforms to the highest specifications and meets the quality standards required.
In addition, over recent years, PBL has implemented a series of initiatives to increase product capacity and have invested over £50m creating state of the art manufacturing facilities including a new 3000L fermentation facility, plus a new filling line and freeze-drying unit. PBL is striving to ensure these new facilities come on-line as soon as possible to meet and exceed future demands for Erwinase®.